Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Cancer Res. 2014 Mar 17;74(11):2962–2973. doi: 10.1158/0008-5472.CAN-13-2421

Fig. 5. TAM Wnt7b deletion suppresses tumor volume, mass and progression.

Fig. 5

(A) Control and mutant inguinal gland volume from 6 weeks to 22 weeks. (B, C) Inguinal gland mass at 16 (B) and 22 (C) weeks. For (B, C) sample number is shown at the base of the chart. Error bars are SEM. (D) Ki67 labeled cells per field for control (MMTV-PyMT; Wnt7btm2Amc/−, C) and mutant (MMTV-PyMT; Wnt7btm2Amc/−; Csf1r-iCre, M) early carcinomas (EC) and late carcinomas (LC). P values as labeled, error bars are SEM. (E) Distribution of the stage of progression for control (C) and mutant (M) MMTV-PyMT mammary tumors at 16 weeks (for control, C, n=18, for mutant, M, n=18) and 22 weeks (for C, n=17, for M, n=9). Hyperplasia and adenoma: H/A, early carcinoma: EC, and late carcinoma: LC.